Free Trial

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Prelude Therapeutics logo
$0.82 0.00 (-0.01%)
Closing price 04:00 PM Eastern
Extended Trading
$0.82 +0.00 (+0.12%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Key Stats

Today's Range
$0.77
$0.85
50-Day Range
$0.78
$1.18
52-Week Range
$0.61
$6.80
Volume
64,297 shs
Average Volume
286,779 shs
Market Capitalization
$46.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Buy

Company Overview

Prelude Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

PRLD MarketRank™: 

Prelude Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 280th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prelude Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Prelude Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Prelude Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prelude Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prelude Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prelude Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Prelude Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.24% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently decreased by 35.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Prelude Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Prelude Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.24% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently decreased by 35.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Prelude Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.95 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    63.90% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Prelude Therapeutics' insider trading history.
Receive PRLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRLD Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

PRLD Stock Analysis - Frequently Asked Questions

Prelude Therapeutics' stock was trading at $1.2750 at the start of the year. Since then, PRLD stock has decreased by 35.7% and is now trading at $0.82.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) released its earnings results on Tuesday, May, 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.05.

Prelude Therapeutics (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/06/2025
Today
7/17/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRLD
CIK
1678660
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$4.00
Potential Upside/Downside
+448.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.17 million
Net Margins
N/A
Pretax Margin
-1,826.10%
Return on Equity
-89.18%
Return on Assets
-69.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.18
Quick Ratio
5.18

Sales & Book Value

Annual Sales
$7 million
Price / Sales
6.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.39 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
56,460,000
Free Float
20,382,000
Market Cap
$46.30 million
Optionable
Optionable
Beta
1.22
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PRLD) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners